Lifeline Biotechnology, Inc.

[fastwalker]

Hey guys..I think we posted this one a while back....

LBTT has pretty good news today!

RENO, Nev., Sep 27, 2004 (BUSINESS WIRE) -- Lifeline Biotechnology, Inc. (Pink Sheets:LBTT) today announced that the company's executives will meet this week to plan a full-scale introduction of the MastaScope(TM) in the American market. The MastaScope is a medical diagnostic tool that provides minimally invasive visualization of breast tissues and abnormalities for patients with Pathological Nipple Discharge.

Dr. William Reeves, Lifeline's founder said: "This is a relatively new concept for detecting breast disease. Although our technology has been under development for more than a decade, few physicians in the world have performed the breast duct endoscopic procedure. For this reason, Lifeline depends on the advice and experience of doctors who are pioneers in training and educating other physicians, many of whom are eager to start offering this new medical procedure to their patients."

Dr. Reeves commented further, "Because we are dealing with new procedures and medical concepts, we must handle them in a manner similar to other medical breakthroughs. Open-heart surgery in the early 1970's, heart-bypass surgery and organ transplants all were amazing and viewed skeptically when they were first introduced. Today they are commonplace. Although the endoscopic procedure for the breast that our MastaScope enables is not as amazing a surgical feat as some of the aforementioned medical procedures, breast ductal endoscopy is certainly as critical and important. Professor Kefah Mokbel of St. George's Hospital and Medical School in London, a leading European breast cancer surgeon, found that breast ductal endoscopy can detect breast cancers when they are 1/100th the size of cancers seen on mammograms or magnetic resonance imaging. We are working to repeat that result with larger patient populations, and should it hold fast, as we believe it will, it will be a tremendous improvement in care for women throughout the world.

"I believe that breast duct endoscopy is here to stay and that this procedure will become an integral part of the war against breast cancer. Lifeline has every intention of working to lead the world with new innovative technologies," said Dr. Reeves.

He noted that as part of its plan for the initial introduction of the MastaScope in the US market, the company is currently in discussions with an eminent breast surgeon to become a part of the launch. The company expects to announce his name and background shortly.

Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's two divisions, Orthopedics Instruments and Cancer Detection technologies, each deal with cutting edge innovation to assist practicing physicians to deliver quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning Systems for assisting in the early detection of breast cancer and the Ovarian Scope for assisting in the early detection of ovarian cancer are continuing to be developed by the company. The Orthopedic division is the exclusive distributor for the Arthronet Shaver Blades in the US, Canada and Mexico and also the exclusive distributor for the Inion bioabsorable screw for the US and Canadian markets. More information is available at the company's website: www.lbti.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe", "experts", "projects", "forecasts", "intends", "will", "anticipated", "could", or "may", and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

SOURCE: Lifeline Biotechnology, Inc.

Martin E. Janis & Company, Inc.
Bev Jedynak, 312-943-1100 ext. 12
[e-mail]